Novo Nordisk announced FDA acceptance of their New Drug Application (NDA) for a 25 mg oral version of Wegovy for two new indications: (1) chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition, and (2) to reduce the risk of MACE in adults with overweight or obesity and established CVD
common brand names include Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide, a dual GIP/GLP-1 drug), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), Byetta and Bydureon (exenatide), Adlyxin (lixisenatide), and Rybelsus (oral semaglutide), with generic options currently including liraglutide and exenatide in some markets
The regulatory pathway for biomarker approval adds additional complexity and delay to clinical implementation (Nisenblat et al., 2016)
Accordingly, we hypothesized that metabolic cholesterol abnormalities may be associated with free carnitine depletion during the fasting period, which warrants further investigation
What Providers Evaluate During Consultation, Provider Assesses: Medical Appropriateness: Does patient meet eligibility criteria
